FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug - Reuters
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOb2M0aXZtM3RvVDBpVnc2V3I2ZXpWc2Q3aVJzY3R5OWw3M0NlOEN4cGExc1liYmh4Mkt6TzBrRjh6YTlVT0tFbzk5aFZnRTAxcUxhSWplX0E2aVdBRWt0bVdJNzR4WGFtM2c2Vi1ZdC13R21qOXFNSkVXeXJnaE9FQTFya2pOY0hCZ3dGVXZfQXZHTUxHSG5YaHBpWkxEUjVQdzhJcUxGeFJyRGhwRGtTTXlVcmxvaGZ0bUR2S3NxYlUxNTZCMG5CNzhPY3YzWTQ?oc=5" target="_blank">FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
US FDA approves Asahi Kasei's drug for persistent herpes infections - Reuters
US FDA approves Asahi Kasei's drug for persistent herpes infections Reuters
October 9, 2026 at 06:01 PMUS FDA flags four deaths in Newron's schizophrenia drug studies - Reuters
US FDA flags four deaths in Newron's schizophrenia drug studies Reuters
October 8, 2026 at 05:47 PMTeva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Teva wins FDA approval for monthly schizophrenia injection Weltruza Reuters
October 9, 2026 at 11:47 AMUS FDA expands use of Novartis drug for chronic skin condition - Reuters
US FDA expands use of Novartis drug for chronic skin condition Reuters
October 7, 2026 at 04:51 PMNvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom - Reuters
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom Reuters
October 8, 2026 at 06:18 PMArgenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
October 8, 2026 at 08:49 PM